Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups

Míreanna comhchosúla

• Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups
  de réir: Lrrzow, MR, et al.
  Foilsithe / Cruthaithe: (2010)
• Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups
  de réir: Lrrzow, MR, et al.
  Foilsithe / Cruthaithe: (2010)
• Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
  de réir: Fielding, A, et al.
  Foilsithe / Cruthaithe: (2010)
• Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
  de réir: Fielding, A, et al.
  Foilsithe / Cruthaithe: (2010)
• Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
  de réir: Fielding, A, et al.
  Foilsithe / Cruthaithe: (2010)